Adam Feuerstein of The Street has laid out his “14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014” list and has a few Bay Area companies in it.
From the article:
“Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Why are these 14 biopharma stock events more important than others? They may not be. Admittedly, my list is subjective, but I tried to highlight the most significant biotech and drug catalysts remaining for 2014. If you think I’m missing something crucial, let me know in the comments section below.”
Here’s the full analysis/list — what do you think?